Medtronic recall spawns inquiry

Little did Medtronic know that it would touch off a Congressional investigation when it recalled a key defibrillator component last week. The Committee on Oversight and Government Reform now is reviewing the FDA's procedures for approving heart-device components.

Committee Chairman Henry Waxman, a longtime U.S. Representative from California, is asking the agency for information on testing procedures for defibrillator leads. Meanwhile, the FDA said it would conduct its own internal review on whether to require lab testing before these products hit the market.

- check out the article from the New York Times

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.